
    
      Subjects will be assessed for eligibility over a 2-week screening period prior to a 2-week
      run-in period and a 12-week double-blind treatment period,4-week follow up period. The
      eligible patients will be randomized to 1 of 3 dose cohorts (A, B, or C). Each patient will
      subsequently be randomized within the designated cohort to active drug or placebo at a 3:1
      active drug:placebo ratio.
    
  